Home
Cell & Gene

Cell & Gene Market Share Analysis for November 2025

04/07/25 Cell & Gene Newsletter

Health > Biotechnology and Pharmaceuticals

Domaincellandgene.com

Year Founded--

Employees51 - 200

Annual Revenue--

Cell & Gene

Cell & Gene (including company regionals)

cellandgene.com

See more website traffic and engagement information

Total visits to Cell & Gene's top domains

Understand Cell & Gene market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

cellandgene.com22.5K

See more with Sales Intelligence

Avg. visit duration in Cell & Gene's top domains

Analyze Cell & Gene engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

cellandgene.com00:00:23

See more with Sales Intelligence

Avg. pageviews on Cell & Gene's top domains

See how Cell & Gene keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

cellandgene.com1.84

See more with Sales Intelligence

Cell & Gene top competitors by domain

Top similar sites in November 2025, ranked by their affinity

pharmasalmanac.comCompany NamePharma's AlmanacEmployees51 - 200HQUnited States, New York, New YorkAnnual revenue$10M - $15MTotal visits11.7KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Cell & Gene

These are the website technologies, by industry, used by Cell & Gene top domains

Advertising (12)

Google Adsense

Social (5)

Google+ Platform

Marketing (4)

Google Marketing Platform

Comments System (3)

Disqus

More Technologies

11

See all

News & Signals from Cell & Gene

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsCellandgene hires Jak Knowles as CEO, and President.Co-Founder, CEO, and President Dr. Jak Knowles joins Cell & Gene: The Podcast Host Erin Harris to discuss how the company engineers immune cells to target oncogenic driver mutations, such as KRAS, the most prevalent oncogenic driver mutation in solid tumors, to minimize potential tumor escape mechanisms.

NewsCellandgene attends event Commercialization Considerations for Orphan/Rare.Here at Asembia's AXS25 Summit in Las Vegas, attendees were treated to behind-the-scenes insight regarding "Commercialization Considerations for Orphan/Rare, Cell & Gene, and Precision Medicine."